1. Home
  2. MIRM vs CASH Comparison

MIRM vs CASH Comparison

Compare MIRM & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • CASH
  • Stock Information
  • Founded
  • MIRM 2018
  • CASH 1954
  • Country
  • MIRM United States
  • CASH United States
  • Employees
  • MIRM N/A
  • CASH N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • MIRM Health Care
  • CASH Finance
  • Exchange
  • MIRM Nasdaq
  • CASH Nasdaq
  • Market Cap
  • MIRM 1.9B
  • CASH 1.9B
  • IPO Year
  • MIRM 2019
  • CASH N/A
  • Fundamental
  • Price
  • MIRM $44.27
  • CASH $82.25
  • Analyst Decision
  • MIRM Strong Buy
  • CASH Buy
  • Analyst Count
  • MIRM 10
  • CASH 2
  • Target Price
  • MIRM $60.80
  • CASH $92.00
  • AVG Volume (30 Days)
  • MIRM 425.9K
  • CASH 229.3K
  • Earning Date
  • MIRM 05-07-2025
  • CASH 04-22-2025
  • Dividend Yield
  • MIRM N/A
  • CASH 0.24%
  • EPS Growth
  • MIRM N/A
  • CASH 10.71
  • EPS
  • MIRM N/A
  • CASH 7.36
  • Revenue
  • MIRM $379,251,000.00
  • CASH $731,383,000.00
  • Revenue This Year
  • MIRM $29.51
  • CASH $13.95
  • Revenue Next Year
  • MIRM $20.27
  • CASH $5.74
  • P/E Ratio
  • MIRM N/A
  • CASH $11.24
  • Revenue Growth
  • MIRM 69.31
  • CASH 6.51
  • 52 Week Low
  • MIRM $23.83
  • CASH $51.97
  • 52 Week High
  • MIRM $54.23
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 56.45
  • CASH 68.58
  • Support Level
  • MIRM $40.00
  • CASH $80.33
  • Resistance Level
  • MIRM $47.43
  • CASH $83.24
  • Average True Range (ATR)
  • MIRM 2.07
  • CASH 1.95
  • MACD
  • MIRM 0.54
  • CASH 0.54
  • Stochastic Oscillator
  • MIRM 65.27
  • CASH 91.95

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: